Principal Investigator
Scott Elman
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20250652
Clinical Trial Summary
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other